feasibility of treatment with bispecifics in patients with myeloma with prior bcma exposure
Published 1 year ago • 88 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
2:29
the safety and feasibility of car-t & bispecifics in patients with myeloma after prior allosct
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
1:14
prevention & monitoring of infections in patients with multiple myeloma treated with immunotherapies
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
4:04
the future of myeloma treatment and the possibility of cure
-
6:09
bispecific antibodies | high impact topic (hit)
-
3:15
what is the best diet for myeloma patients to build a strong immune system?
-
1:27
the value of bispecifics in myeloma & the importance of optimally sequencing immunotherapies
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
1:37
the promise of elranatamab and other bispecifics in the treatment of myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
2:19
feasibility of biomarker-driven strategy in high-risk lbcl: final results from nordic phase ii study
-
2:44
novel bcma-targeting therapies to treat tce relapsed/refractory multiple myeloma
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
9:31
utilizing new understanding in multiple myeloma biology to guide treatment
-
3:13
how to optimally sequence agents in the expanding treatment armamentarium of multiple myeloma